Latest Advances in Lung Cancer Research

Tarlatamab small cell lung cancer research just took a major step forward. A new study in the New England Journal of Medicine found that adding tarlatamab to standard maintenance treatment helped patients live much longer.

Mayo Clinic researchers found genetic and cellular clues, including missing a gene and “zombie cells”, that help explain why some lung tumors respond well to immunotherapy.

A new study shows adding immunotherapy to chemotherapy before lung cancer surgery significantly improves five-year survival rates in patients.

Study of 1,143 lung cancer patients shows improved MET exon 14 mutation detection methods help select better targeted treatments.

The study highlights that the timing of irAEs depends on the specific immunotherapy and recent treatment history.

FDA approves Opdivo for early-stage NSCLC. This immunotherapy can be used before and after surgery, potentially improving outcomes for patients with resectable lung cancer.

Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

A recent multicenter study published in The Lancet highlights the promising efficacy of immunotherapy in advanced lung cancer patients.